Stock · COO · Healthcare
United States · Large Cap · listed since 1983 · Revenue 12 mo. $4.2B
Price as of 11/06/2026
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers.
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Original text from the data provider
Summary
42.2 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €389.2M (2025), it supports €4.3B. The remaining €6B of the market value assume it grows 12.2% a year for 10 years and not at all afterwards.
Required FCF growth per year
12.2%
no growth afterwards
Price to operating cash flow 11.7×, below its usual range.
Middle half of 20 quarters: 18.5× to 28.2×, median 24.9×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q2 → Q3 2026
4 more unchanged: Revenue, 12 mo., Gross margin, Net debt, Shares outstanding
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 4.55% | 11.52% | Rank 16 |
| Return on capital (Greenblatt) | 22.20% | 32.55% | Rank 28 |
| EBIT margin | 16.69% | 18.31% | Rank 46 |
| FCF margin | 10.60% | 14.12% | Rank 36 |
| Gross margin | 60.67% | 60.99% | Rank 49 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 5.06% | 8.04% | Rank 34 |
| Earnings growth, 3 years per year | −1.15% | 5.44% | Rank 33 |
| Earnings growth, 5 years per year | 9.28% | 7.00% | Rank 57 |
| Sustainable growth (ROE × retained earnings) | 8.86% | 3.66% | Rank 91 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 3.01% | 2.90% | Rank 51 |
| FCF yield | 3.76% | 3.63% | Rank 51 |
| EV/saleslower is better | 3.47 | 4.03 | Rank 54 |
| EV/EBITlower is better | 20.78 | 21.73 | Rank 53 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | −19.23% | 8.66% | Rank 19 |
| Share price, 6 months | 4.42% | 24.27% | Rank 22 |
| Share price, 3 months | −10.86% | 15.42% | Rank 1 |
| Distance from 52-week high | −26.04% | −7.35% | Rank 14 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −0.39% | 0.30% | Rank 57 |
| Change in share countlower is better | −0.20% | 0.00% | Rank 55 |
| Dividend streak in years | 15 | 10 | Rank 74 |
| Price reaction to results, market-adjusted | −13.90% | 0.05% | Rank 1 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 66.47% | 48.40% | Rank 74 |
| Net debt/EBITDAlower is better | 2.54 | 1.11 | Rank 23 |
| Debt to equitylower is better | 0.34 | 0.48 | Rank 59 |
| Volatility, 1 yearlower is better | 31.94% | 31.42% | Rank 48 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $M | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2016 | 2.0 | 16.5% | 357.0 | 196M | 1.2 |
| 2017 | 2.1 | 20.1% | 466.4 | 198M | 1.1 |
| 2018 | 2.5 | 15.9% | 475.3 | 199M | 1.9 |
| 2019 | 2.7 | 20.6% | 421.1 | 200M | 1.7 |
| 2020 | 2.4 | 12.8% | 176.2 | 198M | 1.9 |
| 2021 | 2.9 | 17.3% | 524.2 | 199M | 1.4 |
| 2022 | 3.3 | 15.3% | 450.4 | 199M | 2.6 |
| 2023 | 3.6 | 14.8% | 215.0 | 199M | 2.4 |
| 2024 | 3.9 | 18.1% | 288.1 | 200M | 2.5 |
| 2025 | 4.1 | 16.7% | 433.7 | 200M | 2.7 |
1 of 7 StockScorer Score rules met · How the score is built
The Cooper Companies, Inc mainly meets criteria in the Valuation category. Result from 18 strategies checked.
The Cooper Companies, Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
1 of 7 rules met
2 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for The Cooper Companies, Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 33.3 | 30.0 |
| P/B ratio | 1.5 | 4.8 |
| Return on equity (ROE) | 4.6% | 11.5% |
| Equity ratio | 66.5% | 48.4% |
| Debt-to-equity (D/E) | 0.34 | 0.48 |
| Dividend yield | 0.0% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| COO | The Cooper Companies, Incthis page | |
| ALGN | Align Technology Inc | Low1.8 |
| RGEN | Repligen Corporation | locked |
| BAX | Baxter International Inc | Low0.9 |
| SOLV | Solventum Corp. | locked |
| WST | West Pharmaceutical Services Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.